Early-Stage Loss of GALNT6 Predicts Poor Clinical Outcome in Colorectal Cancer.

Ogawa, Makiko; Tanaka, Atsushi; Namba, Kei; Shia, Jinru; Wang, Julia Y; Roehrl, Michael H

Ogawa, Makiko; Tanaka, Atsushi; Namba, Kei; Shia, Jinru; Wang, Julia Y; Roehrl, Michael H.

Afiliación

Ogawa M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Tanaka A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Namba K; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Shia J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Wang JY; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Roehrl MH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Front Oncol ; 12: 802548, 2022.

Article en En | MEDLINE | ID: mdl-35692787

Palabras clave

GALNT6; colorectal cancer; early stage; glycosylation; risk prediction

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google